News for 'Daiichi Sankyo'

Ranbaxy brand may fade away as Sun takes charge

Ranbaxy brand may fade away as Sun takes charge

Rediff.com10 Dec 2014

The joint entity will have a market share of nine per cent in India. Analysts tracking the company said one of the key outcomes of the merger would be to create a single brand entity of Sun and the Ranbaxy brand would eventually dissolve.

Another big blow for Ranbaxy

Another big blow for Ranbaxy

Rediff.com22 Aug 2014

Slapped with Rs 242-crore fine by US authorities for rule violations at Toansa unit, say sources; 2nd such hefty rap in the recent past from US regulators for bending rules.

FDI reforms: Now, pharma in focus

FDI reforms: Now, pharma in focus

Rediff.com18 Jul 2013

FDI in brownfield investment has resulted in acquisition of domestic drug-manufacturing firms by multinational companies.

Sun, Ranbaxy hire Mckinsey for merger assistance

Sun, Ranbaxy hire Mckinsey for merger assistance

Rediff.com18 Jul 2014

Sun-Ranbaxy are keen to complete the merger process.

Ranbaxy may exit small global markets

Ranbaxy may exit small global markets

Rediff.com26 Aug 2013

According to sources, the company has identified smaller markets such as Peru, which do not contribute significantly to profits, where it might shut shop in the near term.

Lessons from the Fortis/Raymond family feuds

Lessons from the Fortis/Raymond family feuds

Rediff.com7 Jan 2019

'Nothing in this world is permanent. So also in business.' 'And more so in family businesses where family issues often influence business decisions,' point out S Subramanian and Nupur Pavan Bang.

Integration challenges: Sun Pharma's next hurdle

Integration challenges: Sun Pharma's next hurdle

Rediff.com23 Apr 2015

The challenge of merging Ranbaxy into the company has not been factored in.

Ranbaxy loses exclusivity on heartburn drug in US

Ranbaxy loses exclusivity on heartburn drug in US

Rediff.com28 Jan 2015

FDA allows Teva to launch Nexium generic; Cipla, which supplies formulation, to gain

How Malvinder and Shivinder Singh destroyed the legacy they inherited

How Malvinder and Shivinder Singh destroyed the legacy they inherited

Rediff.com27 Mar 2018

Over-expansion, bad management, and multiple allegations irreparably taint Malvinder and Shivinder Singh

Winning spree intact; Sensex, Nifty soar 5% in 3 sessions

Winning spree intact; Sensex, Nifty soar 5% in 3 sessions

Rediff.com27 May 2016

Nifty50 surged 87 points to end at 8,157, highest closing levels since Oct 29, 2015.

Walmart's $16 bn Flipkart buy is the biggest deal this year

Walmart's $16 bn Flipkart buy is the biggest deal this year

Rediff.com9 May 2018

Sachin Bansal, who had co-founded Flipkart with Binny Bansal in 2007, would exit the company

FIIs turn to China as they exit Indian markets

FIIs turn to China as they exit Indian markets

Rediff.com8 May 2015

FIIs have offloaded stocks worth Rs 13,110 crore

Sensex falls to four-week closing low; Sun Pharma plunges

Sensex falls to four-week closing low; Sun Pharma plunges

Rediff.com21 Apr 2015

The Sensex ended at at 27,676, lower by 210 points and the Nifty broke the psychological level of 8,400 to end at 83877 down 70 points.

Ranbaxy gets important breather

Ranbaxy gets important breather

Rediff.com11 Oct 2013

Ranbaxy's US factory, Ohm Laboratories, is learnt to have got a clean chit from the American regulator. This US facility was under surveillance of the Food and Drug Administration (FDA) since the end of 2012.

More trouble for Ranbaxy; Mohali unit may also have come under USFDA lens

More trouble for Ranbaxy; Mohali unit may also have come under USFDA lens

Rediff.com24 Jun 2013

FDA inspectors visited the Mohali plant in the process of giving approval to Ranbaxy's application for Valsartan.

Is India losing its key ally?

Is India losing its key ally?

Rediff.com17 May 2017

India is failing to take advantage of its important ally, Japan as much as it should, notes Mihir S Sharma.

US FDA tightens regulatory noose on Indian drug firms

US FDA tightens regulatory noose on Indian drug firms

Rediff.com17 Sep 2013

Import alert on Ranbaxy's Mohali unit; Strides' injectible arm gets warning letter

Drugmakers draw more FDA scrutiny as US imports rise

Drugmakers draw more FDA scrutiny as US imports rise

Rediff.com13 Sep 2013

And when an inspector asked about the contents of unlabelled vials in the laboratory glassware washing area, a plant worker dumped them down a sink and said the contents could not be determined, according to a July 18 letter from the US Food and Drug Administration to Wockhardt, which makes sterile injectable drugs and various forms of insulin.

Pharma in 2014: Deals worth billions and fines worth millions

Pharma in 2014: Deals worth billions and fines worth millions

Rediff.com26 Dec 2014

In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.

Sun Pharma draws up plan to fix ailing Ranbaxy

Sun Pharma draws up plan to fix ailing Ranbaxy

Rediff.com12 Sep 2014

It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues

2018: Year of reckoning for India Inc

2018: Year of reckoning for India Inc

Rediff.com28 Dec 2018

A glance back at some of the important ups and down Indian Inc faced in 2018.

Religare's banking bid under Ranbaxy cloud

Religare's banking bid under Ranbaxy cloud

Rediff.com1 Jun 2013

Singh brothers might be stopped by 'fit & proper' hurdle due to US drug norm violations; firm says confident of qualifying.

« Prev  |